All Symptomatic Polycythemia Vera Patients may Benefit From Treatment With a JAK2 Inhibitor

Patients with polycythemia vera (PV) experience significant symptoms characterized by fatigue, itching, night sweats, bone pain, fever, and undesired weight loss that contribute to a poor quality of life. A recent study indicates the JAK2 inhibitor, ruxolitinib (Jakafi), alleviates these symptoms in many patients.